HUTCHMED(00013),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

00013 HUTCHMED

Not Yet Opened 12-31 12:08:15

22.550

-0.200

-0.88%

High22.650	Low22.050	Vol3.66M
Open22.250	D1 Closing22.750	Amplitude2.64%
Mkt Cap19.66B	Tradable Cap19.66B	Total Shares872.00M
T/O81.38M	T/O Rate0.42%	Tradable Shares872.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"00013","market":"HK","secType":"STK","nameCN":"HUTCHMED","latestPrice":22.55,"timestamp":1735618095025,"preClose":22.75,"halted":0,"volume":3662165,"delay":0,"floatShares":872000000,"shares":872000000,"eps":0.9213369685953752,"marketStatus":"Not Yet Opened","change":-0.2,"latestTime":"12-31 12:08:15","open":22.25,"high":22.65,"low":22.05,"amount":81378669,"amplitude":0.026374,"askPrice":22.55,"askSize":11000,"bidPrice":22.4,"bidSize":2500,"shortable":3,"etf":0,"ttmEps":-0.3816481408120306,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1735781400000},"marketStatusCode":0,"adr":0,"listingDate":1624982400000,"exchange":"SEHK","adjPreClose":22.75,"openAndCloseTimeList":[[1735608600000,1735617600000]],"volumeRatio":2.031165688708681,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00013","defaultTab":"news","newsList":[{"id":"2500895816","title":"China-based Hutchmed to divest stake in health unit for $608 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2500895816","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500895816?lang=en_us&edition=fundamental","pubTime":"2025-01-02 04:09","pubTimestamp":1735762197,"startTime":"0","endTime":"0","summary":"Jan 2  - Hong Kong-headquartered biopharmaceutical company Hutchmed     on Wednesday said it will sell stakes in a health subsidiary to GP Health Service Capital and Shanghai Pharmaceuticals    for about $608 million.  ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1588","BK1191","00013"],"gpt_icon":0},{"id":"2500984831","title":"Li Ka-Shing-Backed Hutchmed Sells Stake in Unit for $608 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2500984831","media":"Bloomberg","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500984831?lang=en_us&edition=fundamental","pubTime":"2025-01-01 19:30","pubTimestamp":1735731032,"startTime":"0","endTime":"0","summary":"Biopharmaceutical firm Hutchmed China Ltd., backed by billionaire Li Ka-shing, has agreed to sell stakes in a health unit for about $608 million as the group seeks to generate capital and focus on its core businesses.","market":"nz","thumbnail":"https://www.bnnbloomberg.ca/resizer/v2/7SACPF4GGHPRD4EUL4MBDRPTWY.jpg?smart=true&auth=6078596d95c5f34a2633ed9c03828cd4736847abf0ae851a68bf39a66b59de9b&width=500&height=333","type":0,"news_type":0,"thumbnails":["https://www.bnnbloomberg.ca/resizer/v2/7SACPF4GGHPRD4EUL4MBDRPTWY.jpg?smart=true&auth=6078596d95c5f34a2633ed9c03828cd4736847abf0ae851a68bf39a66b59de9b&width=500&height=333"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.bnnbloomberg.ca/business/company-news/2025/01/01/li-ka-shing-backed-hutchmed-sells-stake-in-unit-for-608-million/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"bnn_bloomberg_highlight","symbols":["BK1588","BK1587","00013","BK1191"],"gpt_icon":0},{"id":"2500309983","title":"BRIEF-HUTCHMED Announces $608 Mln Divestment Of Non-Core Joint Venture","url":"https://stock-news.laohu8.com/highlight/detail?id=2500309983","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500309983?lang=en_us&edition=fundamental","pubTime":"2025-01-01 18:53","pubTimestamp":1735728784,"startTime":"0","endTime":"0","summary":"Jan 1  - HUTCHMED  Ltd   :   * HUTCHMED ANNOUNCES US$608 MILLION DIVESTMENT OF NON-CORE JOINT VENTURE   * HUTCHMED  LTD - DIVESTMENT PROCEEDS TO ADVANCE HUTCHMED'S PIPELINE AND CORE INNOVATIVE MEDICINES BUSINESS   * HUTCHMED  LTD - HUTCHMED EXPECTS TO RECORD A GAIN ON DISPOSAL OF APPROXIMATELY US$477 MILLION BEFORE TAXATIONSource text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JYNT","BK1588","BK1191","00013","BK1587","BK4185"],"gpt_icon":0},{"id":"2500983904","title":"HUTCHMED- Entered Two Agreements to Divest 45% Equity Interest in Shanghai Hutchison Pharmaceuticals to Gp Health Service Capital, Shanghai Pharmaceuticals Holding","url":"https://stock-news.laohu8.com/highlight/detail?id=2500983904","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500983904?lang=en_us&edition=fundamental","pubTime":"2025-01-01 18:46","pubTimestamp":1735728405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250101:nTUA2RBG6H:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0187","BK0196","BK0184","BK1587","601607","BK0188","BK0183","BK0012","BK1191","BK1588","00013","BK0209","BK0099","BK0028","BK0097","BK0175","BK0020"],"gpt_icon":0},{"id":"2500983834","title":"HUTCHMED (China) Ltd - Divestment Proceeds to Advance HUTCHMED's Pipeline and Core Innovative Medicines Business","url":"https://stock-news.laohu8.com/highlight/detail?id=2500983834","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500983834?lang=en_us&edition=fundamental","pubTime":"2025-01-01 18:46","pubTimestamp":1735728405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250101:nTUA2RBG6H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1588","BK0188","00013","BK0184","BK0012","BK0020","BK0183","BK0209","BK0196","BK1587","BK0028","BK1191","601607","BK0097","BK0099","BK0187","BK0175"],"gpt_icon":0},{"id":"2500838849","title":"HUTCHMED Announces US$608 Million Divestment of Non-Core Joint Venture","url":"https://stock-news.laohu8.com/highlight/detail?id=2500838849","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500838849?lang=en_us&edition=fundamental","pubTime":"2025-01-01 18:46","pubTimestamp":1735728405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250101:nTUA2RBG6H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0028","BK1587","BK1191","BK0196","BK0188","BK0012","BK0209","BK0184","BK0175","BK0020","601607","BK1588","BK0187","BK0097","BK0183","BK0099","00013"],"gpt_icon":0},{"id":"2500838319","title":"HUTCHMED (China) Ltd - HUTCHMED Expects to Record a Gain on Disposal of Approximately US$477 Mln Before Taxation","url":"https://stock-news.laohu8.com/highlight/detail?id=2500838319","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500838319?lang=en_us&edition=fundamental","pubTime":"2025-01-01 18:46","pubTimestamp":1735728405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250101:nTUA2RBG6H:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0012","BK0028","BK0175","BK0188","BK0209","BK0187","BK1191","BK0196","BK1587","BK0097","BK0184","601607","BK1588","BK0099","00013","BK0020","BK0183"],"gpt_icon":0},{"id":"2500983836","title":"Press Release: HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture","url":"https://stock-news.laohu8.com/highlight/detail?id=2500983836","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500983836?lang=en_us&edition=fundamental","pubTime":"2025-01-01 18:46","pubTimestamp":1735728360,"startTime":"0","endTime":"0","summary":"-- HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to patients globally --. -- Divestment proceeds to advance HUTCHMED's pipeline and core innovative medicines business --. -- Focused R&D investment includes HUTCHMED's proprietary antibody-targeted therapy conjugate platform, with first candidates expected to enter clinical trials in the second half of 2025 --. HUTCHMED plans to invest the proceeds from these transactions to further develop its internal pipeline and drive its core business strategy forward. This pipeline and strategy includes its next-generation antibody drug conjugate  platform, which builds on HUTCHMED's extensive knowledge from pursuing oncological pathways and proven expertise in small molecule targeted therapeutics. By combining antibodies with targeted therapeutics instead of cytotoxins, these antibody-targeted therapy conjugates  offer dual mechanisms for addressing ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","JYNT","BK4185","00013","HCM","BK1587","BK4531","BK4588","BK1191","BK1588","BK4007"],"gpt_icon":0},{"id":"2492225851","title":"Daiwa Securities Initiates Coverage on HUTCHMED With Buy Rating, $23 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2492225851","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492225851?lang=en_us&edition=fundamental","pubTime":"2024-12-19 20:40","pubTimestamp":1734612014,"startTime":"0","endTime":"0","summary":"Daiwa Securities Initiates Coverage on HUTCHMED With Buy Rating, $23 Price Target","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HCM","00013"],"gpt_icon":0},{"id":"2491422163","title":"Hutchmed to Receive $10 Million Milestone Payment Through Takeda","url":"https://stock-news.laohu8.com/highlight/detail?id=2491422163","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491422163?lang=en_us&edition=fundamental","pubTime":"2024-12-13 17:59","pubTimestamp":1734083995,"startTime":"0","endTime":"0","summary":"Hutchmed (HCM) said late Thursday it will receive a $10 million milestone payment through its partner Takeda (TAK) following a national reimbursement recommendation in Spain for Fruzaqla as a treatmen","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1588","BK1191","00013","BK4531","BK1587","BK4585","BK4588","BK4007","HCM","TAK"],"gpt_icon":0},{"id":"2491312399","title":"BRIEF-Hutchmed China Ltd Will Receive $10 Mln Milestone Payment By Its Partner Takeda","url":"https://stock-news.laohu8.com/highlight/detail?id=2491312399","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491312399?lang=en_us&edition=fundamental","pubTime":"2024-12-13 15:17","pubTimestamp":1734074248,"startTime":"0","endTime":"0","summary":"BRIEF-Hutchmed China Ltd Will Receive $10 Mln Milestone Payment By Its Partner TakedaDec 13 (Reuters) - HUTCHMED (China) Ltd 0013.HK:HUTCHMED (CHINA) LTD: WILL RECEIVE $10 MILLION MILESTONE PAYMENT BY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241213:nFWN3ND12P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1588","00013","BK1587","BK1191"],"gpt_icon":0},{"id":"2491314435","title":"HUTCHMED (China) Ltd: Will Receive $10 Mln Milestone Payment by Its Partner Takeda","url":"https://stock-news.laohu8.com/highlight/detail?id=2491314435","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491314435?lang=en_us&edition=fundamental","pubTime":"2024-12-13 15:04","pubTimestamp":1734073492,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241213:nFWN3ND12P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1588","00013","BK1587","BK1191"],"gpt_icon":0},{"id":"2491856390","title":"HUTCHMED (China) to Receive $10 Million Milestone Payment From Takeda After First European Reimbursement for Fruzaqla","url":"https://stock-news.laohu8.com/highlight/detail?id=2491856390","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491856390?lang=en_us&edition=fundamental","pubTime":"2024-12-13 12:23","pubTimestamp":1734063784,"startTime":"0","endTime":"0","summary":"HUTCHMED   said it will receive a $10 million milestone payment from its partner Takeda Pharmaceutical , which received a national reimbursement recommendation in Spain in December 2024, according to a Friday filing with the Hong Kong Stock Exchange.The national reimbursement Takeda received is the first in Europe and relates to Fruzaqla  for patients with previously treated metastatic colorectal cancer, the filing said.Outside of China, Macau, and Hong Kong, Takeda has the exclusive worldwide license to develop further, commercialize, and manufacture fruquintinib, which treats colorectal cancer, according to the filing.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1587","BK1191","00013","BK1588"],"gpt_icon":0},{"id":"2491616673","title":"HUTCHMED to Receive Milestone Payment From Takeda Following First European Reimbursement for Fruzaqla® (Fruquintinib)","url":"https://stock-news.laohu8.com/highlight/detail?id=2491616673","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491616673?lang=en_us&edition=fundamental","pubTime":"2024-12-13 08:00","pubTimestamp":1734048002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241213:nTUA3N3YBN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1588","BK1587","BK1191","00013"],"gpt_icon":0},{"id":"2491536119","title":"HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)","url":"https://stock-news.laohu8.com/highlight/detail?id=2491536119","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491536119?lang=en_us&edition=fundamental","pubTime":"2024-12-13 08:00","pubTimestamp":1734048000,"startTime":"0","endTime":"0","summary":"— US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe— — Follows June 2024 European approval of FRUZAQLA (fruquintinib), the first novel oral targeted therapy in","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/13/2996584/0/en/HUTCHMED-to-Receive-Milestone-Payment-from-Takeda-following-First-European-Reimbursement-for-FRUZAQLA-fruquintinib.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013","TAK","BK4007","BK1588","BK1191","BK1587"],"gpt_icon":0},{"id":"2490803467","title":"China Grants Hutchmed Breakthrough Designation for Non-Small Cell Lung Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2490803467","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490803467?lang=en_us&edition=fundamental","pubTime":"2024-12-12 18:33","pubTimestamp":1733999616,"startTime":"0","endTime":"0","summary":"China's medical products administrator granted Hutchmed  breakthrough therapy designation for its combination of savolitinib and osimertinib for a mutation of non-small cell lung cancer, according to a Thursday filing with the Hong Kong Exchange.The drug combination is undergoing phase 3 trials in China, the filing said.The breakthrough designation is given to drugs that treat life-threatening illnesses with no known treatment options and with clinical evidence showing advantages over other existing therapies, the filing said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["00013","BK1588","BK1587","BK1191"],"gpt_icon":0},{"id":"2490874718","title":"HUTCHMED Secures Breakthrough Therapy Designation in China for Lung Cancer Drug Combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2490874718","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490874718?lang=en_us&edition=fundamental","pubTime":"2024-12-12 17:02","pubTimestamp":1733994121,"startTime":"0","endTime":"0","summary":"HUTCHMED  said late Wednesday that China's National Medical Products Administration has granted breakthrough therapy designation to Orpathys in combination with Tagrisso to treat non-small cell lung cancer patients.The designation qualifies the treatment candidate for a potential conditional approval and priority review, the company said.The drug cocktail is currently being evaluated in a phase 3 trial in China.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK1587","BK1191","BK1588","00013","HCM","BK4531","BK4585","BK4007"],"gpt_icon":0},{"id":"2490790588","title":"BRIEF-Hutchmed (China) Says Breakthrough Therapy Designation For Orpathys And Tagrisso Combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2490790588","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490790588?lang=en_us&edition=fundamental","pubTime":"2024-12-12 16:35","pubTimestamp":1733992542,"startTime":"0","endTime":"0","summary":"Dec 12 (Reuters) - HUTCHMED (China) Ltd   :   * BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR ORPATHYS AND TAGRISSO COMBINATION IN CERTAIN LUNG CANCER PATIENTS Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1588","BK1191","00013","BK1587"],"gpt_icon":0},{"id":"2490582363","title":"HUTCHMED Announces Breakthrough Therapy Designation in China for Orpathys® and Tagrisso® Combination in Certain Lung Cancer Patients After Disease Progression on Egfr Inhibitor Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2490582363","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490582363?lang=en_us&edition=fundamental","pubTime":"2024-12-12 12:00","pubTimestamp":1733976002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241212:nTUA8HY2N9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1588","BK1191","00013","BK1587"],"gpt_icon":0},{"id":"2490823496","title":"HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2490823496","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490823496?lang=en_us&edition=fundamental","pubTime":"2024-12-12 12:00","pubTimestamp":1733976000,"startTime":"0","endTime":"0","summary":"HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec.  11, 2024  (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation o","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/12/2995863/0/en/HUTCHMED-Announces-Breakthrough-Therapy-Designation-in-China-for-ORPATHYS-and-TAGRISSO-Combination-in-Certain-Lung-Cancer-Patients-After-Disease-Progression-on-EGFR-Inhibitor-Thera.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS","BK1191","BK1588","BK4097","BK1587","BK4135","00013","CNS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hutch-med.com","stockEarnings":[{"period":"1week","weight":0.0067},{"period":"1month","weight":-0.1491},{"period":"3month","weight":-0.3187},{"period":"6month","weight":-0.1725},{"period":"1year","weight":-0.2143},{"period":"ytd","weight":-0.2143}],"compareEarnings":[{"period":"1week","weight":-0.0019},{"period":"1month","weight":0.0328},{"period":"3month","weight":-0.1062},{"period":"6month","weight":0.1127},{"period":"1year","weight":0.1767},{"period":"ytd","weight":0.1767}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.130873},{"month":2,"riseRate":0.666667,"avgChangeRate":0.058734},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.131658},{"month":4,"riseRate":0.666667,"avgChangeRate":0.04977},{"month":5,"riseRate":0,"avgChangeRate":-0.194502},{"month":6,"riseRate":0.333333,"avgChangeRate":0.018958},{"month":7,"riseRate":1,"avgChangeRate":0.135989},{"month":8,"riseRate":0.25,"avgChangeRate":-0.055482},{"month":9,"riseRate":0.5,"avgChangeRate":-0.020796},{"month":10,"riseRate":0.25,"avgChangeRate":-0.032252},{"month":11,"riseRate":0.5,"avgChangeRate":0.182346},{"month":12,"riseRate":0.5,"avgChangeRate":-0.016836}],"exchange":"SEHK","name":"HUTCHMED","nameEN":"HUTCHMED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"HUTCHMED(00013),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest HUTCHMED(00013) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"HUTCHMED,00013,HUTCHMED股票,HUTCHMED股票老虎,HUTCHMED股票老虎国际,HUTCHMED行情,HUTCHMED股票行情,HUTCHMED股价,HUTCHMED股市,HUTCHMED股票价格,HUTCHMED股票交易,HUTCHMED股票购买,HUTCHMED股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"HUTCHMED(00013),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest HUTCHMED(00013) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}